Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Summary of Significant Accounting Policies

Schedule of the fair value measurements within the fair value hierarchy of the Company's financial instruments

			Fair value at September 30, 2024
	Total		Level 1		Level 2		Level 3
Assets:
Cash Equivalents
Mutual Funds	$	1,237	$	1,237	$	—	$	—
Money Market Funds		18		18		—		—
Total assets	$	1,255	$	1,255	$	—	$	—
Liabilities
Royalties payable	$	9,797	$	—	$	—	$	9,797
Total liabilities	$	9,797	$	—	$	—	$	9,797

			Fair value at December 31, 2023
	Total		Level 1		Level 2		Level 3
Assets:
Cash Equivalents
Mutual Funds	$	3,397	$	3,397	$	—	$	—
Money Market Funds		10		10		—		—
Total assets	$	3,407	$	3,407	$	—	$	—
Liabilities
Royalties payable	$	6,974	$	—	$	—	$	6,974
Total liabilities	$	6,974	$	—	$	—	$	6,974

Schedule of Significant unobservable inputs used in the fair value measurement

	September 30, 2024
Instrument	Valuation Technique	Unobservable Input	Input Range
Royalties Payable	Discounted future cash flows	Revenue adjusted discount rate	20%
	December 31, 2023
Instrument	Valuation Technique	Unobservable Input	Input Range
Royalties Payable	Discounted future cash flows	Revenue adjusted discount rate	28%

Schedule of Property and Equipment Estimated Useful Lives

Machinery and equipment	2-5 years
Computer hardware and software	1-5 years
LockeT animation video	3 years
VIVO DEMO/Clinical Systems	1-5 years

Schedule of disaggregated product sales by geographic area

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2024		2023		2024		2023
Product Sales
US	$	62	$	110	$	129	$	241
Europe		34		23		142		73
	$	96	$	133	$	271	$	314